SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Drug Price Gouging Enters Spotlight as Candidates Take on Big Pharma
Bernie Sanders and Hillary Clinton among those calling for reforms to pharmaceutical marketplace
Sep 22, 2015
Amid a growing scandal over two pharmaceutical companies' price hikes on two vital medications, voices from the political sphere are promising renewed action to tackle price gouging in the medical marketplace.
On Sunday, Turing Pharmaceuticals increased overnight the price of Daraprim, a malaria medication, from $12.50 to $750 a pill. Around the same time, a separate drug company, Rodelis Therapeutics, sent the cost of tuberculosis drug Cycloserine from $15 to $360 a pill.
After ensuing outrage, Rodelis rescinded the increase and handed Cycloserine back to the nonprofit organization from which it had purchased ownership of the drug brand. But Turing refused to back down.
Turing CEO Martin Shkreli defended his company's actions from widespread criticism, telling Bloomberg TV about the Daraprim decision, "This drug saves your life for $50,000. At this price, it's a no-brainer."
Shkreli's actions and cavalier defense did little to soothe public furor. But among the continued outcry, some politicians stepped up with their own solutions to the issue of unregulated medication costs.
Hillary Clinton on Monday tweeted, "Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on."
While the official plan will not be unveiled until the Democratic presidential candidate's speech in Iowa later Tuesday, early reports indicate that it would force pharmaceutical companies to reinvest profits into disease and treatment research and allow Medicare to lower and cap out-of-pocket expenses for consumers.
Bernie Sanders, Clinton's current chief rival for the nomination, has also sponsored legislation that would allow Medicare to negotiate drug prices with pharmaceutical companies. Many of the provisions in his bill are echoed in Clinton's new plan.
Sanders also sent Turing a letter on Monday demanding information on the company's price hike.
"The enormous, overnight price increase for Daraprim is just the latest in a long list of skyrocketing price increases for certain critical medications," Sanders said in a joint statement with Rep. Elijah E. Cummings (D-Md.), ranking member of the House Committee on Oversight and Government Reform.
"Without fast access to this drug, used to treat a very serious parasitic infection, patients may experience organ failure, blindness or death," Sanders and Cummings said.
Indeed, Daraprim is widely considered one of the best medications for toxoplasmosis or people whose immune systems are weakened by HIV/AIDS or cancer. The Infectious Diseases Society of America slammed Turing's action, saying it burdens patients and creates unsustainable costs for the country's healthcare system.
Big Pharma has come under fire in recent weeks over its unregulated control over drug prices. A recent survey by the Kaiser Family Foundation found that more than 70 percent of Americans feel medication prices are unreasonably high and that drug companies put their own profits above people's medical needs.
And Shkreli does not disagree. In fact, he used it as his defense, telling CBS News, "The drug was unprofitable at the former price, so any company selling it would be losing money. And at this price it's a reasonable profit. Not excessive at all."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Nadia Prupis
Nadia Prupis is a former Common Dreams staff writer. She wrote on media policy for Truthout.org and has been published in New America Media and AlterNet. She graduated from UC Santa Barbara with a BA in English in 2008.
Amid a growing scandal over two pharmaceutical companies' price hikes on two vital medications, voices from the political sphere are promising renewed action to tackle price gouging in the medical marketplace.
On Sunday, Turing Pharmaceuticals increased overnight the price of Daraprim, a malaria medication, from $12.50 to $750 a pill. Around the same time, a separate drug company, Rodelis Therapeutics, sent the cost of tuberculosis drug Cycloserine from $15 to $360 a pill.
After ensuing outrage, Rodelis rescinded the increase and handed Cycloserine back to the nonprofit organization from which it had purchased ownership of the drug brand. But Turing refused to back down.
Turing CEO Martin Shkreli defended his company's actions from widespread criticism, telling Bloomberg TV about the Daraprim decision, "This drug saves your life for $50,000. At this price, it's a no-brainer."
Shkreli's actions and cavalier defense did little to soothe public furor. But among the continued outcry, some politicians stepped up with their own solutions to the issue of unregulated medication costs.
Hillary Clinton on Monday tweeted, "Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on."
While the official plan will not be unveiled until the Democratic presidential candidate's speech in Iowa later Tuesday, early reports indicate that it would force pharmaceutical companies to reinvest profits into disease and treatment research and allow Medicare to lower and cap out-of-pocket expenses for consumers.
Bernie Sanders, Clinton's current chief rival for the nomination, has also sponsored legislation that would allow Medicare to negotiate drug prices with pharmaceutical companies. Many of the provisions in his bill are echoed in Clinton's new plan.
Sanders also sent Turing a letter on Monday demanding information on the company's price hike.
"The enormous, overnight price increase for Daraprim is just the latest in a long list of skyrocketing price increases for certain critical medications," Sanders said in a joint statement with Rep. Elijah E. Cummings (D-Md.), ranking member of the House Committee on Oversight and Government Reform.
"Without fast access to this drug, used to treat a very serious parasitic infection, patients may experience organ failure, blindness or death," Sanders and Cummings said.
Indeed, Daraprim is widely considered one of the best medications for toxoplasmosis or people whose immune systems are weakened by HIV/AIDS or cancer. The Infectious Diseases Society of America slammed Turing's action, saying it burdens patients and creates unsustainable costs for the country's healthcare system.
Big Pharma has come under fire in recent weeks over its unregulated control over drug prices. A recent survey by the Kaiser Family Foundation found that more than 70 percent of Americans feel medication prices are unreasonably high and that drug companies put their own profits above people's medical needs.
And Shkreli does not disagree. In fact, he used it as his defense, telling CBS News, "The drug was unprofitable at the former price, so any company selling it would be losing money. And at this price it's a reasonable profit. Not excessive at all."
Nadia Prupis
Nadia Prupis is a former Common Dreams staff writer. She wrote on media policy for Truthout.org and has been published in New America Media and AlterNet. She graduated from UC Santa Barbara with a BA in English in 2008.
Amid a growing scandal over two pharmaceutical companies' price hikes on two vital medications, voices from the political sphere are promising renewed action to tackle price gouging in the medical marketplace.
On Sunday, Turing Pharmaceuticals increased overnight the price of Daraprim, a malaria medication, from $12.50 to $750 a pill. Around the same time, a separate drug company, Rodelis Therapeutics, sent the cost of tuberculosis drug Cycloserine from $15 to $360 a pill.
After ensuing outrage, Rodelis rescinded the increase and handed Cycloserine back to the nonprofit organization from which it had purchased ownership of the drug brand. But Turing refused to back down.
Turing CEO Martin Shkreli defended his company's actions from widespread criticism, telling Bloomberg TV about the Daraprim decision, "This drug saves your life for $50,000. At this price, it's a no-brainer."
Shkreli's actions and cavalier defense did little to soothe public furor. But among the continued outcry, some politicians stepped up with their own solutions to the issue of unregulated medication costs.
Hillary Clinton on Monday tweeted, "Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on."
While the official plan will not be unveiled until the Democratic presidential candidate's speech in Iowa later Tuesday, early reports indicate that it would force pharmaceutical companies to reinvest profits into disease and treatment research and allow Medicare to lower and cap out-of-pocket expenses for consumers.
Bernie Sanders, Clinton's current chief rival for the nomination, has also sponsored legislation that would allow Medicare to negotiate drug prices with pharmaceutical companies. Many of the provisions in his bill are echoed in Clinton's new plan.
Sanders also sent Turing a letter on Monday demanding information on the company's price hike.
"The enormous, overnight price increase for Daraprim is just the latest in a long list of skyrocketing price increases for certain critical medications," Sanders said in a joint statement with Rep. Elijah E. Cummings (D-Md.), ranking member of the House Committee on Oversight and Government Reform.
"Without fast access to this drug, used to treat a very serious parasitic infection, patients may experience organ failure, blindness or death," Sanders and Cummings said.
Indeed, Daraprim is widely considered one of the best medications for toxoplasmosis or people whose immune systems are weakened by HIV/AIDS or cancer. The Infectious Diseases Society of America slammed Turing's action, saying it burdens patients and creates unsustainable costs for the country's healthcare system.
Big Pharma has come under fire in recent weeks over its unregulated control over drug prices. A recent survey by the Kaiser Family Foundation found that more than 70 percent of Americans feel medication prices are unreasonably high and that drug companies put their own profits above people's medical needs.
And Shkreli does not disagree. In fact, he used it as his defense, telling CBS News, "The drug was unprofitable at the former price, so any company selling it would be losing money. And at this price it's a reasonable profit. Not excessive at all."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.